International Biotechnology Trust
International Biotechnology Trust, established in 1994 and based in Wales, United Kingdom, provides investors with access to the rapidly growing biotechnology sector through an actively managed, diversified fund. The trust is managed by a team from SV Health Investors, with over 60 years of combined experience in the field. It invests primarily in a diverse portfolio of global quoted biotechnology stocks, while also including selected unquoted investments aimed at delivering long-term returns. The investment strategy focuses on excellent management teams, innovative products, and strong potential for outperformance. Under the leadership of Lead Investment Manager Carl Harald Janson, the trust has achieved notable performance, significantly surpassing its benchmark and the FTSE All-Share Index over recent years. International Biotechnology Trust aims to deliver both high capital growth and sustainable dividend income, appealing to investors interested in the biotechnology landscape.
Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, that specializes in the development of innovative medicines for cancer. Established in 2005, the company focuses on designing and developing orally-active small molecule drugs aimed at targeting specific molecular pathways. Its notable products include KA2237, a dual-selective inhibitor of PI3K isoforms p110ß and p110d, designed for treating both hematological and solid tumors, and KA2507, an HDAC6 inhibitor intended for tumors expressing PD-L1. Karus Therapeutics aims to address unmet medical needs in oncology through its targeted therapeutic approaches.
Oxagen Limited, a biopharmaceutical company, develops and commercializes anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhinoconjunctivitis. Its drug programs target the CRTH2 receptor that initiates and maintains allergic conditions. The company develops a pipeline of small molecule drugs. It serves customers in the United Kingdom, Russia, CIS countries, and internationally. Oxagen Limited was incorporated in 1996 and is based in London, United Kingdom.
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
GlycoFi Inc.
Series C in 2005
GlycoFi is a biotech firm that develops biotherapeutics based on the glycan optimization technology. The firm aims to develop its own pipeline of therapeutic proteins and team with other drug-makers to develop products. GlycoFi has developed a protein manufacturing process using yeast-based glycolysation where the resulting proteins can be used in drug development. GlycoFi was incorporated in 2000 and is based in Lebanon, New Hampshire. As of June 6, 2006, GlycoFi, Inc. operates as a subsidiary of Merck & Co. Inc.
Oxagen Limited, a biopharmaceutical company, develops and commercializes anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhinoconjunctivitis. Its drug programs target the CRTH2 receptor that initiates and maintains allergic conditions. The company develops a pipeline of small molecule drugs. It serves customers in the United Kingdom, Russia, CIS countries, and internationally. Oxagen Limited was incorporated in 1996 and is based in London, United Kingdom.
Aderis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovery, development and commercialization of products for the diagnosis and treatment of cardio-renal diseases. Discovery Therapeutics' product pipeline includes adenosine agonists and antagonists for the diagnosis and treatment of cardiovascular disease and leukotriene synthesis inhibitors for the treatment of chronic renal disease. In addition the company has license agreements with strategic partners involving novel late stage products for the treatment of Parkinson's disease and diagnosis of coronary artery disease.
eBioinformatics is a Bioinformatics Service Provider. They deliver innovative and broad-ranging bioinformatics services to the worldwide bioscience research effort. The difficulty of managing the flood of data generated by biomedical and biotechnology research is the inspiration behind eBioinformatics ' products. eBioinformatics emphasises accessibility and usability so that bioscientists, whether they are working in academic, government or corporate research, are empowered by the ability to analyze and manage the large quantities of data they produce.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.